Grace Therapeutics, Inc. (GRCE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Prashant Kohli | CEO & Director | 599.97k | -- | 1972 |
| Mr. Amresh Kumar Ph.D. | VP of Program Management | 353.5k | -- | 1980 |
| Ms. Carrie D'Andrea | VP of Clinical Operations | 359.05k | -- | 1972 |
| Mr. Robert J. DelAversano CPA | VP of Finance and Principal Financial & Accounting Officer | -- | -- | 1972 |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer | -- | -- | 1962 |
Grace Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
March 12, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission